This study is looking at how safe and effective two medicines, called **remibrutinib** and **teriflunomide**, are for people with a condition called **relapsing multiple sclerosis (RMS)**. RMS is a type of disease where the immune system attacks the brain and spinal cord, causing problems like weakness and vision issues. The first part of the study lasts up to 30 months and involves about 800 people. The second part can last up to 5 years for those who continue with remibrutinib. To join, you must be between 18-55 years old, have a diagnosis of RMS, and meet specific health criteria.

• Study duration can be up to 5 years.
• Participants will receive medication and regular health check-ups.
• Risks include potential drug side effects, requiring regular monitoring.

Note: You cannot join if you have other serious health conditions, are pregnant, or have a history of substance abuse. Always consult with your doctor to see if this study is right for you.